• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Glythera makes appointments to support company expansion

Glythera makes appointments to support company expansion

April 3, 2014
CenterWatch Staff

Glythera, a biotechnology company specializing in the development of next generation bio-therapeutics, including Antibody Drug Conjugates,  through the application of its proprietary linker and stable glycan technologies PermaLink and PermaCarb, has appointed of Nigel Burns as non-executive director and Ian Evetts as commercial director. Glythera has recently validated data from their core technologies and the addition of Burns and Evetts coincides with the company’s expansion plan exploring new opportunities to provide essential support during the company’s growth plan.

Burns brings over 25 years experience in the biopharmaceuticals and biotechnology industry to Glythera. He has extensive experience leading product management and has held a series of leadership roles including, senior vice president of Cambridge Antibody Technology, non-executive director of Navion, chairman of Cell Medica, director and founder of Nascient and most recently, CEO and founder of SweetSpot Therapeutics. As non-executive director, Burns will support the development of Glythera’s  technology and future business strategies, bringing new levels of focus and innovation to the company’s offerings.

Evetts joins Glythera with over 20 years experience in the pharmaceutical industry. He has a track record of senior strategic and operational roles including, managing director at Atebion BDS, strategic advisor at Bionure and business development and portfolio director at AstraZeneca. As commercial director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies, a key growth area for Glythera.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing